Adocia, a clinical-phase biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides, today announces that it will be holding an oral presentation on the M1Pram bi-hormonal treatment (ADO09) at the 81st edition of the scientific sessions of the American Diabetes Association (ADA) which will take place from June 25 to 29, 2021 as a virtual event.
The first key results obtained as part of this study were published via a press release dated September 15, 2020.
During this oral presentation, Gregory Meiffren, Director of Clinical Development at Adocia will present the study and the main results obtained.
Date & Heure : Sun, Jun 27 (Eastern)- 4:00pm – 4:15pm Intitulé : 197-OR – ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram), Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1D.
Speaker: Grégory Meiffren, PhD; Duration: 15 min.
Adocia is currently carrying out a Phase 2 study with M1Pram and results are expected in the second quarter of 2022.
–
